Ratings Navamedic ASA

Equities

NAVA

NO0010205966

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-10 EDT			5-day change	1st Jan Change
33.1 ^NOK	-0.90%		+1.53%	-9.81%

05-06	Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	MT
04-30	Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
With regards to fundamentals, the enterprise value to sales ratio is at 0.94 for the current period. Therefore, the company is undervalued.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NAVAMEDIC ASA	-9.81%	53.2M	-
ELI LILLY AND COMPANY	+30.38%	684B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	329B	B-
ABBVIE INC.	+3.73%	284B	C+
ASTRAZENECA PLC	+16.70%	240B	B+
NOVARTIS AG	+8.78%	208B	B-
ROCHE HOLDING AG	-7.93%	200B	A+
AMGEN INC.	+7.68%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes